Preliminary results from a phase 1b double-blind study to assess the safety, tolerability and efficacy of intra-articular administration of resiniferatoxin or placebo for the treatment of moderate to severe pain due to osteoarthritis of the knee

医学 脂毒素 骨关节炎 耐受性 安慰剂 麻醉 沃马克 慢性疼痛 不利影响 TRPV1型 外科 内科学 物理疗法 受体 替代医学 瞬时受体电位通道 病理
作者
David A. Leiman,Harold S. Minkowitz,Roy C. Levitt,D. Solanki,D. Horn,David Janfaza,Dawn M. Sarno,N. Albores-Ibarra,X. Bai,Kenzo Takeshita,Tiefu Zhao,C. Lu,P. Bharathi,Jennifer Ahern,S. Klincewicz,Srdjan S. Nedeljkovic
出处
期刊:Osteoarthritis and Cartilage [Elsevier BV]
卷期号:28: S138-S138 被引量:8
标识
DOI:10.1016/j.joca.2020.02.228
摘要

Purpose: Osteoarthritis (OA) is a degenerative disease marked by breakdown of joint cartilage and associated bony changes. A dominant symptom is pain, which can become severe to the point where the patient is a candidate for joint replacement surgery. Although a wide range of analgesics and therapeutics are available, pain frequently remains an intractable problem. Even after total knee replacement, chronic knee pain has been reported in up to a third of patients. Resiniferatoxin (RTX) is a potent TRPV1 calcium channel agonist. RTX exposure results in prolonged calcium influx and ablation of TRPV1-positive nerve endings. In preclinical osteoarthritis models, RTX treatment leads to selective neurolysis of TRPV1-expressing pain sensory fibers and leaves sensory and motor neuron functions intact. We report on the preliminary safety and efficacy results from a phase 1B trial of resiniferatoxin administered intra-articularly as a one-time injection in subjects with moderate to severe pain due to knee osteoarthritis. Methods: In this multicenter, randomized, double-blind, placebo-controlled study, eligible subjects aged 35-85 years, with baseline pain score in the index knee of ≥5 but ≤9 (WOMAC pain subscale question A1) were treated with a one-time intra-articular dose of resiniferatoxin at escalating dose level cohorts of 5, 12.5, 20 and 30 mcg in 5 or 10 mL of saline, or saline placebo. For each 8-subject cohort the first subject received open-label RTX. Upon confirmation of safety in this sentinel subject, the remaining 7 subjects (5 RTX: 2 PBO) were enrolled in a blinded fashion. After confirmation of safety at each dose level by an independent DMC, the next higher dose level was opened for enrollment. Safety and efficacy data were collected over a twelve-week period. Subjects could be unblinded after a protocol-specified time period. Additional follow-up to 52 weeks was optional. Efficacy was assessed using the subject reported WOMAC and NPRS pain scores. Results: Enrollment of all planned dose escalation cohorts is complete, with 30 subjects receiving RTX and 10 receiving placebo. 70% are female and 30% are male. Median age is 62 years (range 44-83), and baseline WOMAC A1 score was mean 6.5 (S.D. 1.4). No dose-limiting toxicities were reported, and the maximum tolerated dose was not reached. The most frequently reported treatment-emergent adverse events were procedure-associated pain (post-procedural pain), which was reported in 80% of placebo subjects and in 100% of RTX subjects. This procedure-associated pain was reported as mild in severity in all placebo subjects, and mild in 73% and moderate in 27% of RTX subjects. Procedure-associated pain was managed with IV fentanyl, PO oxycodone, and other analgesics on the day of the injection. Typically, the pain subsided before being discharged that same day and subsided within 24 hours in all subjects. Other adverse events (reported in at least 2 RTX-treated subjects) were nausea (43%), vomiting and arthralgia (17%), hypertension and headache (10%) and hypoaesthesia (7%). Most events were mild, the few moderate events were of short duration; none were severe. There was no apparent relationship between adverse events and dose levels. In the secondary endpoint of efficacy, reduction in subject reported WOMAC A1 pain scores was observed at most dose levels. The difference in the mean score for WOMAC A1 (pain on walking on flat surface) at week 12 between the placebo subjects and RTX treated subjects expressed as the least squares mean difference (LSMD) in change from baseline relative to placebo, ranged from -0.04 to -2.63 points depending on the dose level cohort. By mixed model repeated measures (MMRM) analysis, the greatest pain reduction was observed at the 12.5 mcg dose (LSMD) versus placebo at 12 weeks of -2.63 by WOMAC A1 score (p = 0.0311, N=6) and -14.58 by WOMAC A pain index (p = 0.0134, N = 6). Compared to baseline pain by WOMAC A1, >70% reduction in the pain was achieved in 50% of pooled RTX-treated subjects and in 83% of the subjects at the 12.5 mcg dose. Pain reduction by RTX as assessed by the daily subject-reported NPRS pain scores were consistent with the WOMAC A1 data. Of the subjects dosed with RTX who have provided voluntary long-term follow-up, 3 of 4 subjects who have reached one year have maintained response. Conclusions: Resiniferatoxin demonstrated safety when given as one-time intra-articular injection up to the planned highest dose of 30 mcg. Preliminary efficacy was also observed. Anecdotal long-term follow up suggests sustained pain relief beyond Day 365. The clinical trial remains open to expansion cohorts to assess further the safety and efficacy at candidate doses to be implemented in future trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xtutang完成签到,获得积分10
刚刚
1秒前
慕青的应助被森林木采纳,获得10
3秒前
Star1983发布了新的文献求助10
4秒前
碧蓝的幻悲完成签到 ,获得积分10
4秒前
null的应助被Sisyphus采纳,获得10
4秒前
cheng程完成签到,获得积分10
5秒前
葛甲率完成签到,获得积分20
5秒前
亚迪完成签到,获得积分10
7秒前
钱念波发布了新的文献求助10
7秒前
夏至未至完成签到,获得积分10
7秒前
8秒前
Lv完成签到,获得积分10
9秒前
聪明的煎蛋完成签到,获得积分10
10秒前
俊秀的千万完成签到,获得积分10
11秒前
wq完成签到 ,获得积分10
12秒前
12秒前
zz完成签到 ,获得积分10
12秒前
13秒前
寒冷晓夏完成签到,获得积分10
14秒前
14秒前
zs完成签到,获得积分10
15秒前
Buduan完成签到,获得积分10
15秒前
忧伤的平安完成签到,获得积分10
16秒前
故剑情深1994完成签到,获得积分10
16秒前
小帅完成签到,获得积分10
16秒前
fangyuan完成签到,获得积分10
16秒前
郑成功完成签到,获得积分10
17秒前
行走的车完成签到,获得积分10
17秒前
17秒前
maple完成签到 ,获得积分10
18秒前
钱念波完成签到,获得积分10
18秒前
现代的紫霜完成签到,获得积分10
18秒前
19秒前
yjw0526完成签到,获得积分10
19秒前
酥梨完成签到,获得积分10
20秒前
完美世界的应助被邢一采纳,获得10
20秒前
Jx小曾完成签到 ,获得积分10
20秒前
乐乐乐完成签到,获得积分10
21秒前
lee完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159151
求助须知:如何正确求助?哪些是违规求助? 9554617
关于积分的说明 21719982
捐赠科研通 7748814
什么是DOI,文献DOI怎么找? 3427149
关于科研通互助平台的介绍 2552091
邀请新用户注册赠送积分活动 2471436